Pet Cloning Market Report 2026

The pet cloning market size has grown rapidly in recent years. It will grow from $4.32 billion in 2025 to $4.99 billion in 2026 at a compound annual growth rate (CAGR) of 15.4%. The growth in the historic period can be attributed to development of somatic cell nuclear transfer techniques, growing interest in pet biotechnology, early research in gene editing for pets, rising pet ownership in affluent regions, advancements in veterinary biotechnology.

The pet cloning market size is expected to see rapid growth in the next few years. It will grow to $8.28 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to expansion of genetic preservation programs, increasing awareness and acceptance of pet cloning, technological innovations in cloning methods, growth in luxury pet services, rising investment in research institutes and breeding centers. Major trends in the forecast period include rising demand for personalized pet cloning services, increasing research in genetic preservation of pets, growth in ethical and legal discussions around pet cloning, adoption of advanced cloning techniques in companion animals, expansion of cloning services in luxury pet markets.

The rising pet ownership rates are expected to drive the growth of the pet cloning market in the coming years. Pet ownership refers to the responsibility and care assumed by individuals or households for the needs, well-being, and companionship of domesticated animals kept primarily for pleasure rather than utility. Rising pet ownership is driven by lifestyle changes, pet humanization, and higher disposable incomes. Pet cloning provides owners the opportunity to preserve the genetic identity of beloved animals, offering continuity and emotional comfort in the companionship experience. For example, in April 2025, according to the Canadian Animal Health Institute, a Canada-based trade association, Canada was home to an estimated 7.2 million dogs and 8.2 million cats in 2024, making pets a central part of over half of Canadian households. Therefore, rising pet ownership rates are supporting growth in the pet cloning market.

The increasing disposable income and pet-related spending are also expected to propel the growth of the pet cloning market. Pet spending refers to financial expenditures by individuals, households, or entities on goods, services, and care associated with owning and maintaining companion animals. Rising disposable income and pet spending are driven by stronger economic growth and the trend of treating pets as family members, prompting greater investment in their care and well-being. Higher disposable income supports pet cloning by enabling owners to afford the high costs of advanced reproductive technologies, reflecting a willingness to invest in preserving cherished pets and extending emotional bonds. For instance, in February 2025, according to a report published by Pet Business Professor, a US-based agency, U.S. pet owners spent approximately $13.42 billion on pet services, up 8.5% from $12.36 billion in 2022, indicating sustained growth in grooming, boarding, and pet care services. Therefore, rising disposable income and pet spending are driving growth in the pet cloning market.

In November 2025, Colossal Biosciences Inc., a US-based biotechnology company specializing in de-extinction, genetic engineering, and conservation biology solutions, acquired Viagen Pets and Equine for an undisclosed amount. Through this acquisition, Colossal aimed to accelerate and scale its animal cloning and genetic preservation capabilities, enhancing its technological platform and expanding market reach into commercial pet cloning services and advanced reproductive technologies for companion animals, livestock, and endangered species. Viagen Pets and Equine is a US-based provider of advanced animal cloning, genetic preservation, and cryopreservation services for pets, equine, livestock, and endangered species.

Major companies operating in the pet cloning market are Trans Ova Genetics, Genetix Biotech Asia Pvt. Ltd., PPL Therapeutics, VectorBuilder Inc., Sinogene Pet Cloning, ViaGen LC, BioArts International, Boyalife Group, Cuddle clones, Gemini Genetics, PERPETUATE INC, Sooam Biotech, Oak Villlage Animal Hospital, Bella Vista Animal Hospital, BioVenic, Cyagra LLC, Embryll Life Sciences, My friend Again, Petslify, RNL Bio.

North America was the largest region in the pet cloning market in 2025. The regions covered in the pet cloning market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pet cloning market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the pet cloning market by increasing costs for imported lab equipment, reagents, and advanced biotechnology tools, particularly impacting segments such as deceased pet cloning and advanced gene editing techniques in regions like north america, europe, and asia-pacific. While costs for end users have risen, tariffs have encouraged local manufacturing of cloning materials and reagents, driving regional innovation and reducing reliance on imports, ultimately supporting the development of domestic cloning services.

The pet cloning market research report is one of a series of new reports that provides pet cloning market statistics, including pet cloning industry global market size, regional shares, competitors with a pet cloning market share, detailed pet cloning market segments, market trends and opportunities, and any further data you may need to thrive in the pet cloning industry. This pet cloning market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pet cloning is a biotechnological procedure used to create a genetically identical replica of a pet animal. This is typically accomplished through somatic cell nuclear transfer (SCNT), where the nucleus of a donor cell is inserted into an egg cell that has had its nucleus removed. The resulting embryo is then transferred into a surrogate mother to develop into a cloned pet with the same genetic makeup as the original animal.

The primary types of pet cloning include deceased pet cloning and live pet cloning. Deceased pet cloning involves creating a genetic duplicate of a deceased pet using preserved cells or tissues to replicate its characteristics and traits. The technology involved in pet cloning includes somatic cell nuclear transfer, gene editing, and other techniques, serving various applications across species such as dogs, cats, horses, birds, reptiles, and more. The end users of pet cloning technology include pet owners, research institutes, breeding centers, zoos, and conservation programs.

The pet cloning market consists of revenues earned by entities by providing services such as genetic counseling services, veterinary support for cloning procedures, DNA banking services, and post-cloning care and rehabilitation programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The pet cloning market also includes sales of cloning kits, genetic preservation solutions, pet cloning equipment sales, and customized cloning protocols. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.